Canakinumab (ACZ885) is a recombinant human IL-1beta-targeting monoclonal antibody that inhibits human and chorioallantoic monkey IL-1beta with IC50 values of 43.6 and 40.8 pM, respectively. It exhibits anti-inflammatory activity by neutralizing IL-1beta signaling, and it has been used for the treatment of gout and coronary artery disease.
Purity:
98.30%
CAS Number:
[914613-48-2]
Target:
Interleukin|||IL Receptor
T73695
T73695
* VAT and and shipping costs not included. Errors and price changes excepted
